Navigation Links
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Date:1/7/2008

disorder that causes exceptionally high levels of LDL-cholesterol. After appropriate clinical development, the next indication pursued for mipomersen will be for other patients with high cholesterol at high risk of cardiovascular events.

Deal Terms

Isis will transition development responsibility for mipomersen to Genzyme over the next two years. In addition to the up-front payment, Isis also has the opportunity to receive from Genzyme up to $825 million in development and regulatory milestone payments plus up to $750 million in commercial milestone payments.

Genzyme and Isis will share mipomersen profits 50/50 when annual worldwide revenues reach $2 billion or more. The profit share begins with a 70/30 Genzyme/Isis split and reaches 50/50 on a sliding scale as annual revenues ramp up to $2 billion.

"Genzyme is reconfirming its 2008 and five-year earnings guidance, and we will manage the financial impact of this agreement within our previously stated goal of 20 percent compound annual growth in non-GAAP earnings per share through 2011," noted Mr. Termeer.

"We believe the profit sharing transaction we have structured with Genzyme is uniquely beneficial to Isis," added Dr. Crooke. "It allows us to benefit in the short term and over time through up-front licensing fees and milestones, while retaining substantial economic participation in the commercialization of the drug. We look forward to working with Genzyme on mipomersen as well as potentially on drugs for CNS and certain rare diseases."

Closure of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

About Familial Hypercholesterolemia (FH)

FH patients have high blood concentrations of LDL-cholesterol due to a genetic disorder which prevents proper metabolism of LDL-cholesterol. These patients experience a markedly increased risk of premature cardiovascular diseases (CVD) and CVD-related death. Familial hypercholestero
'/>"/>

SOURCE Genzyme Corp.; Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
2. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
3. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
4. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
5. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
6. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
7. Genzyme Launches Cholestagel(R) in Europe
8. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
9. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
10. Genzyme Recognized by Scientists as a Top Employer
11. Genzyme Receives Approval to Market Elaprase(R) in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Custom Learning Designs, Inc.(CLD) unveils the ... Tin Can API combined with its own proprietary ... leading developer of training content and solutions for ... , Tin Can API is a cost-effective learning ... more accurately measure the Return on Education (ROE) ...
(Date:5/21/2013)... 2013 Alpha Source, Inc., a ... be exhibiting for the 13th consecutive year at ... (AAMI) 2013 Conference and Expo. The conference brings ... manufacture healthcare technologies. This year’s event will be ... , The three-day event draws over 1,500 ...
(Date:5/21/2013)... May 21, 2013 Clinverse, ... company for clinical trials, announced today it has ... LLC. Clinverse’s ClinPay® FLS eClinical commerce platform ... process. SpendMD ™, Aggregate Spend Solutions’ ... for tracking and reporting transfer of value at ...
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2
... 22, 2011  Intimate Bridge 2 Conception, Inc. (Ib2C™), a ... reproductive health, announced today that it has closed on ... led by a private, Pennsylvania-based investment group and was ... the proceeds of this round for manufacturing and marketing ...
... provider of comprehensive scientific management solutions, biomaterial storage and ... to announce the company has donated proceeds raised from ... for the Cure ® Tissue Bank at the ... to the Komen Tissue Bank on Monday, December 12th, ...
... 2011  MedTRACK, an Informa business unit, and the ... recently unveiled a premier partnering tool for the ... delegates attending the conference find licensing, investment and ... Partnering Filter companies can quickly identify like-minded suitors ...
Cached Biology Technology:Intimate Bridge 2 Conception, Inc. Receives $4.3M 2Intimate Bridge 2 Conception, Inc. Receives $4.3M 3BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research 2BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research 3MedTRACK Unveils Partnering Tool for J.P. Morgan Healthcare Conference 2
(Date:5/20/2013)... University of Minnesota Medical School researchers from the ... the University,s Brain Tumor Program, have developed a new ... that allow them to discover new genes and gene ... was published this week in the journal Nature ... researchers in the lab of David Largaespada, Ph.D., professor ...
(Date:5/20/2013)... Ohio New research suggests that a compound abundant ... to escape death. , By altering a very ... cancer cells into normal cells that die as scheduled. ... inhibiting a process that would cause them to die ... programming. This study in cells, led by Ohio State ...
(Date:5/20/2013)... the University of Bristol and published online today in ... on how the brain and inner ear developed in ... Earth Sciences, together with Tom Hbner from the Niederschsische ... million year old dinosaurs. , The two palaeontologists studied ... : a very young (juvenile) individual of approximately ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3Fossil brain teaser 2
... Hlldobler , one of the world,s great ant experts and ... give the 2010 Alfred M. Boyce Lecture at the University ... titled "The Superorganism: Communication and Cooperation in Ant Societies," will ... 1102A, followed by a reception at 5 p.m. in the ...
... the fluorescent lighting in supermarkets actually can boost the ... finding could lead to improved ways of preserving and ... veggies, they suggest in a study in ACS, bi-weekly ... Gene Lester, Donald J. Makus, and D. Mark Hodges ...
... scientific "Renaissance man" whose work spans the fields ... Lieberman-Aiden, graduate student at the Harvard-MIT Division of ... winner of the prestigious $30,000 Lemelson-MIT Student Prize. ... Student Prize winners announced today, was selected for ...
Cached Biology News:Leading entomologist to give talk at UCR on communication and cooperation in ant societies 2MIT student inventor honored for transformative work in genomics and linguistics 2MIT student inventor honored for transformative work in genomics and linguistics 3
ERalpha (Ser 104/106)...
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Agarose, pulse field, 100 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Biology Products: